Introduction
IKAROS, a transcription factor encoded by IKZF1, is expressed during hematopoiesis (1, 2) . It has been involved in positive regulation of lymphocyte differentiation and negative regulation of cell proliferation (3) . IKAROS (designated herein as IKZF1) also plays some role in peripheral lymphocyte homeostasis, mainly by favoring a Th2 response in T cells and negatively regulating follicular B cell activation (4, 5) . Additional roles of IKZF1 in the development of myeloid cells, including neutrophils, basophils, platelets, and red blood cells, have been shown in different models (6) (7) (8) (9) .
IKZF1 is mainly composed of 2 functional domains: an N-terminal DNA-binding domain (DBD) formed by 4 zinc fingers (ZF) and a C-terminal dimerization domain consisting of 2 additional ZFs. More than 10 isoforms of IKZF1 have been described and can be found in normal hematopoietic cells. Some isoforms lack one or more DBD ZF and are considered to behave as dominant negative (10) . IKZF1 binding to DNA occurs at pericentromeric heterochromatin (PC-HC) regions; IKZF1 functions primarily as a gene repressor by interacting with the Ikaros/IKZF1 is an essential transcription factor expressed throughout hematopoiesis. IKZF1 is implicated in lymphocyte and myeloid differentiation and negative regulation of cell proliferation. In humans, somatic mutations in IKZF1 have been linked to the development of B cell acute lymphoblastic leukemia (ALL) in children and adults. Recently, heterozygous germline IKZF1 mutations have been identified in patients with a B cell immune deficiency mimicking common variable immunodeficiency. These mutations demonstrated incomplete penetrance and led to haploinsufficiency. Herein, we report 7 unrelated patients with a novel early-onset combined immunodeficiency associated with de novo germline IKZF1 heterozygous mutations affecting amino acid N159 located in the DNA-binding domain of IKZF1. Different bacterial and viral infections were diagnosed, but Pneumocystis jirovecii pneumonia was reported in all patients. One patient developed a T cell ALL. This immunodeficiency was characterized by innate and adaptive immune defects, including low numbers of B cells, neutrophils, eosinophils, and myeloid dendritic cells, as well as T cell and monocyte dysfunctions. Notably, most T cells exhibited a naive phenotype and were unable to evolve into effector memory cells. Functional studies indicated these mutations act as dominant negative. This defect expands the clinical spectrum of human IKZF1-associated diseases from somatic to germline, from haploinsufficient to dominant negative.
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were not found in public exome databases. Mutations were confirmed by Sanger sequencing and analyzed in the available family members. No such changes were detected in the relatives tested, which suggests the mutations were de novo in at least 6 of the 7 patients ( Figure 1A ). Of note, the 2 Japanese patients (families B and F) have been previously reported, but the relationship between their IKZF1 genotype and their clinical phenotypes was not to our knowledge examined in depth (2, 19) . Amino acid sequence alignment of the 4 ZF domains contained in the DBD of IKZF1 indicated that the residue N159 and the other residues previously involved in haploinsufficient mutations are at positions -1, -4, -7, and -8 relative to the first histidine in the 4 ZF domains ( Figure 1C ). All these positions are known to be involved in DNA binding (20) and are highly conserved across species, which highlights their importance for the function of IKZF1 ( Figure 1D ). Supporting a key role of the N159 residue, p.N159A mutation was previously tested and shown to behave as a dominant-negative mutation in vitro, while its effect in vivo has not been described in animal models or extensively evaluated in humans (18, 21) .
Clinical and immunologic phenotype of patients with heterozygous IKZF1
N159S/T mutations. All patients carrying IKZF1 N159 heterozygous missense mutations became symptomatic early in life: 3 within their first 6 months of life, and all of them by the age of 15 months. Pneumocystis jirovecii pneumonia was diagnosed in all patients between the ages of 6 and 24 months; this was the first clinical manifestation in 2 and occurred multiple times in 2 patients (Table 1) . Other infectious complications included invasive bacterial respiratory tract infections in 6 patients, severe or recurrent viral infections in 5, superficial or invasive fungal infections in 4, and liver cryptosporidiosis associated with sclerosing cholangitis and secondary cirrhosis in 1 patient (A1). No autoimmune diseases were identified. T cell acute lymphoblastic leukemia (T-ALL) was diagnosed in 1 patient (F1) at the age of 13 years (2) . Three patients received hematopoietic stem cell transplants (HSCTs) before their genetic diagnosis was established, 2 for CID during childhood and the other for T-ALL (2) . Despite transplantation, one of the patients with severe immune deficiency died from infectious complications (R. Marsh, unpublished observations).
Profound hypogammaglobulinemia affecting the major isotypes and severe B cell lymphopenia were detected in 7 patients at diagnosis of immunodeficiency (Table 2 ). IgE was low or undetectable in 5 of them. Severe T cell lymphopenia was found in 2 (E1 and transiently during early infancy in F1, although it was originally diagnosed as severe combined immunodeficiency; ref. Table 2 , and Supplemental Figure 1 ; supplemental material available online with this article; https://doi. org/10.1172/JCI98164DS1), although CD45RA was expressed at low density ( Figure 2 , A and B, and Supplemental Figure 1 ). These cells also exhibited the phenotype of recent thymic emigrants (CD45RA + CD31 + ) ( Table 2 and Figure 2C ), with the exception of cells from patient E1 (the only adult in our series who also was found to have a hypocellular bone marrow) ( Table 2) . Inversely, central memory and effector memory T cells were decreased in NurD complex (11, 12) . IKZF1 acts as a homodimer, but it may also work as a heterodimer by associating with other IKAROS isoforms or family members, such as IKZF2 (HELIOS), IKZF3 (AIOLOS), and IKZF4 (EOS) (3) .
Several mouse models have been generated in the past 20 years and confirmed the key role of IKZF1 in lymphoid and myeloid development. Ikzf1-deficient null mice in which the dimerization domain was removed showed a severe lymphoid development arrest (13) . Ikzf1-deficient null mice also exhibited myeloid development abnormalities, including absence of DCs, increased basophils, and increased megakaryocytes (7, 8, 13) . Ikzf1 L/L mice, expressing low levels of Ikaros, showed increased myeloid precursors with impaired migratory potential and increased susceptibility to cell death at the embryonic stage; adult mice showed a near 2-fold reduction in peripheral blood neutrophils (6) . ENU-induced Plastic mice harboring the missense mutation p.H191R in the DBD ZF3 in homozygosity showed embryonic lethality with severe anemia and defects in granulocyte differentiation, increased macrophage formation, and blocked lymphoid development. Heterozygous animals had normal lymphoid development until the second month of life and then invariably developed T cell lymphoid malignancy, which underlines the role of murine Ikaros in controlling lymphoid proliferation (10, (13) (14) (15) . The severity of this dominant-negative effect at the heterozygous state was linked to its action over the WT Ikaros allele and also toward Aiolos (14) .
In humans, somatic IKZF1 mutation mainly by deletion has been linked to B cell ALL (B-ALL) development in children and adults and constitutes an adverse prognostic factor in Philadelphia chromosomepositive pediatric B-ALL (16, 17) . More recently, germline mutations have been described in patients with common variable immunodeficiency (CVID) associated with B cell immune deficiency, B-ALL susceptibility, and autoimmune manifestations (18, 19) . Although no clinical T cell defects were evident among these patients, elevated naive and central memory CD3 + CD8 + T cells not related to increased cellular proliferation, decreased cell death, clonal expansion, or specific viral infections were detected. All mutations were heterozygous with incomplete penetrance and included deletions and missense mutations affecting IKZF1 DBD. Functional studies showed that these mutations acted by haploinsufficiency (18) .
In the present study, we describe a new early-onset combined immunodeficiency (CID) syndrome caused by particular de novo heterozygous germline IKZF1 mutations detected in 7 unrelated patients. Myeloid defects were also a prominent part of the biological picture. All the mutations were located in ZF2, affecting the IKZF1 DBD, and in vitro functional studies demonstrated these to be dominant-negative mutations.
Results

Identification of heterozygous IKZF1
N159S/T mutations in 7 patients with combined immunodeficiency. Whole-exome sequencing was performed in patients with genetically uncharacterized CID from France, Japan, and the United States. Seven patients carried heterozygous IKZF1 missense mutations at position chr7:50450292: 6 presented with a c.476A>G transition leading to an asparagineto-serine change at amino acid 159 (p.N159S) and 1 an A>C transversion leading to an asparagine-to-threonine change at the same site (p.N159T) (Figure 1, A and B) . IKZF1 N159S or T mutations 3 0 7 3 jci.org
Volume 128 Number 7 July 2018 2+ coordination (bottom connecting lines), except for ZF4, in which the last histidine is replaced by a cysteine (strictly conserved in the Ikaros-like family). Amino acids at positions -1, -4, -7, and -8 relative to the first histidine (i.e., 0) are known to be involved in DNA binding (19) . Mutated amino acids are colored in pink (this study) or orange (previous studies). The ZF predicted secondary structures (deduced from the model of 3D structure shown in Supplemental Figure 8 ) are shown below the alignment. (D) Alignment of ZF domains of IKZF1 family members including IKZF1/ IKAROS, IKZF2/HELIOS, IKZF3/AIOLOS, and IKZF4/EOS. Sequences of species from the Chordata phylum including marine Urochordata (Ciona and Oikopleura) and primitive fish such as hagfish are aligned. Red stars indicate residues found to be mutated in patients. All these residues are highly conserved through species. Figure 2A ). Double-negative T (DNT) cells were elevated in the 2 patients tested. T cell receptor Vβ (TCR-Vβ) flow cytometric analysis was performed in 4 patients, and TCR-Vα spectratyping analysis was done in 1 (data not shown). Neither of these tests revealed any abnormalities, which suggests that the T cell repertoire is normal and unaffected in patients. NK cell count was normal or slightly reduced in all patients. Eosinophils were undetectable in 6 patients tested. Mild to moderate chronic neutropenia was detected in 5 of 7 patients as early as in their second year of life, and myeloid DCs were reduced in the 2 patients tested ( Table 2 and see below). T cell defects in patients with heterozygous IKZF1 N159S/T mutations. The in vitro immunophenotype of T cells from patients and healthy controls was evaluated by flow cytometry on peripheral blood mononuclear cells (PBMCs) that were phytohemagglutinin-stimulated (PHA-stimulated) and maintained in culture for 10 days ( Figure 2D ). Naive T cells from healthy controls progressively declined to less than 2% at the end of the study, but naive T cells from patients remained consistently high at more than 38% during the entire culture period. Inversely, effector memory T cells progressively increased at least to 44% in healthy controls, as patients' cells remained low at less than 10% after 10 days in culture. While central memory T cells were decreased at time 0 in patient cell cultures, they reached levels similar to those of healthy controls at the end of the study. A differential analysis of targeted RNA sequencing (RNA-Seq) data was evaluated between unstimulated naive CD4 + T cells from 2 patients carrying IKZF1 Figure 2A) . Proliferation of patients' T cells was markedly reduced in response to a low dose of immobilized anti-CD3 (1 μg/ml), soluble anti-CD3 plus CD28 (1 μg/ml each), or antigen stimulation with tetanus toxoid or candida antigen ( Figure 3A , Figure 4C , and Table 2 ). In contrast, T cell proliferation to PHA, a high dose of immobilized anti-CD3 (10 μg/ml), or anti-CD3/CD28-coated beads was normal. Addition of IL-2 did not rescue the proliferation defect ( Figure 3B ). While the expression of IL-2 receptor chains CD25, CD122, and CD132 was readily detected on the surface of the patients' T cells (Supplemental Figure 3A and data not shown), CD25 was not upregulated on T cells after stimulation with a low dose of immobilized anti-CD3 with or without IL-2 ( Figure 3C ). Moreover, STAT5 phosphorylation upon IL-2 stimulation was markedly impaired in CD4 + cells, a pattern that could also reflect the strong reduction of CD4 + memory T cells in the patients (Supplemental Figure 3B ). These observations strongly suggest that defective CD25 upregulation and the unresponsiveness to IL-2 contribute to defective T cell proliferation in addition to the reduced response to low doses of anti-CD3. Consistent with an impaired response to IL-2, natural regulatory T cell (CD4 + CD25 + FoxP3 + ) numbers were found to be diminished in 3 IKZF1
N159S patients and the IKZF1
N159T patient tested (Table 2 and Supplemental Figure   3A ). Cytokine production by patient T cells was also selectively impaired. While IL-2 production by patient T cells was normal in response to either PMA/ionomycin or CD3/CD28-coated beads, a marked defect in IFN-γ, TNF-α, IL-4, IL-6, and IL-17A production to the latter stimuli was observed ( Figure 3 , D-F, and Supplemental Figure 4 ). Taken together, these results demonstrate that germline IKZF1 N159S and IKZF1 N159T mutations are associated with an immune deficiency characterized by defects in effector memory T cell generation, T cell activation, signaling, proliferation as well as cytokine production after TCR engagement. Furthermore, defects in IFN-γ/TNF-α, IL-4/IL-6, and IL-17A production indicate that Th polarization from Th0 toward Th1, Th2, and Th17 subsets (respectively) is markedly impaired in the 3 patients tested. These defects likely reflect both the strong reduction of CD4 + memory T cells in the patients and the accumulation of abnormal naive T cells with an impaired phenotype.
B cell defects associated with heterozygous IKZF1 N159S/T mutations. Analysis of the B cell compartment in patients with IKZF1 N159S mutation showed strikingly reduced B cells in peripheral blood (Table 2 ). In contrast, patient G1, who carries the unique germline mutation resulting in IKZF1 N159T , showed normal although progressively declining B cell numbers with only a naive phenotype (Table 2) Figure 5 ). In contrast to those patients, plasma cells were virtually absent in their bone marrow biopsies, suggesting a more dramatic effect over B cell development (data not shown).
Myeloid defects associated with heterozygous IKZF1 N159S/T mutations. Myeloid defects, indicative of a multilineage defect in hematopoiesis, were also detected in the patients (Table 2) . Two patients (B1 and E1) had mild chronic anemia and 3 (A1, F1, and G1) exhibited low-normal erythrocyte mean corpuscular volumes without evidence of inflammation or iron deficiency. Hemoglobin electrophoresis performed in G1 was normal. Eosinophils were undetectable in all patients tested. In addition, 5 patients had chronic mild to moderate neutropenia (absolute neutrophil count [ANC] <1,000/μl and >200/μl), 2 of them requiring G-CSF treatment with adequate responses. Bone marrow aspirates performed in patients C1 and D1 because of neutropenia showed decreased granulopoiesis with no erythroid or megakaryocytic abnormalities. Cytogenetic analysis did not demonstrate abnormalities, and no anti-neutrophil antibodies were detected. Patient E1, the oldest patient in the series, had a hypocellular bone marrow with myeloid hypoplasia and mild megakaryocytic atypia; B cells and plasma cells were also drastically reduced (data not shown). Monocyte counts were normal in 5 of 7 patients (reduced in E1 and F1). Low myeloid as well as normal-low plasmacytoid DC numbers were observed in the 2 patients tested (B1 and G1) ( Table 2 and Figure 4A ). Targeted RNA-Seq was also done in LPS-stimulated monocytes from patients carrying IKZF1 N159S/T mutants, healthy controls, and 2 patients carrying haploinsufficient mutation IKZF1 H167R . Analysis of data revealed significantly differentially expressed transcripts between cells carrying mutants IKZF1 Figure 2B ). In correlation with their abnormal transcript expression, monocyte proinflammatory cytokine production of IL-1β, IL-6, and TNF-α evaluated in 3 patients was severely impaired in response to agonists triggering Toll-like receptor 1/2 (TLR1/2) (Pam3CSK4), TLR2 (HKLM), TLR4 (LPS), TLR5 (FLA-ST), and TLR6/2 (FSL1) pathways ( Figure 4B ), while adequate responses (Figure 6 , B and C). Experiments using tagged forms of mutants and WT IKZF1 showed similar results (Supplemental Figure 6 ). At the 25:75 ratio, mutant IKZF1
N159T formed more foci than IKZF1 N159S ( Figure 6C ). Coexpression of IKZF1 N159S or IKZF1 N159T with IKZF3 (AIOLOS) in a 50:50 ratio resulted in heterodimerization and inhibition of IKZF3 foci formation associated with diffused nuclear localization of IKZF3, similar to what was seen with IKZF1 (Supplemental Figure 7) .
These data demonstrate that IKZF1 N159S and IKZF1 N159T mutant proteins are expressed, and can dimerize and migrate to the nucleus, where they exert a dominant-negative effect on WT IKZF1, in terms of formation of foci within the nucleus, in contrast to the findings of the previously described haploinsufficient IKZF1 mutants (e.g., IKZF1
R162Q ). Of note, the IKZF1 N159S mutant exhibited a stronger dominant-negative effect on formation of foci than the IKZF1 N159T , in accordance with the clinical and biological presentations of the IKZF1 N159T patient, which are less pronounced. Finally, IKZF1 N159S and IKZF1 N159T can also exert a trans-dominant-negative effect on IKZF1 partners such as IKZF3.
Discussion
Herein we describe a new autosomal dominant CID caused by IKZF1 N159S/T mutations found in 7 unrelated patients. This disorder is characterized by a T cell defect affecting activation, signaling, proliferation, T-helper (Th) polarization, and memory generation, with susceptibility to Pneumocystis pneumonia prior to the age of 2 years. This condition, similar to the previously described IKZF1 haploinsufficiency defect, is also associated with impaired B cell development and maintenance, resulting in loss of B cells in most cases. Additionally, there are myeloid abnormalities including neutropenia, eosinopenia, quantitative defects in myeloid DCs, and abnormal monocyte function that likely contribute to the T cell defect. All these findings are consistent with hematopoietic pan-expression of IKZF1. This defect also likely predisposes to an increased risk of T-ALL, as was previously reported in 1 patient in our series (2) .
Besides P. jirovecii pneumonia, most patients also developed severe respiratory bacterial (pneumococci, klebsiella, and pseudomonas) or viral (respiratory syncytial virus [RSV], influenza A, and adenovirus) infections. Interestingly, other microbes ap peared to be better neutralized among IKZF1 N159 S/T patients. While 2 individuals received live viral vaccines (either measles-mumps-rubella [MMR] or oral poliovirus vaccine) and 3 were bacillus Calmette-Guérin (BCG) vaccinated, neither of them experienced complications related to the vaccines. Moreover, 2 patients presented with chickenpox with uncomplicated courses. Several factors might have contributed to this protection toward particular infectious agents. Although these patients exhibited marked T cell defects, T cell proliferative responses to high-dose CD3 or to costimulation with CD3/CD28-coated beads were normal. This residual proliferation capacity upon stronger stimulation might be sufficient to control certain infections. Moreover, normal responses to type I and type II interferons were detected in these patients (data not shown), both critical for the control of viral and to IFN-α and IFN-γ (by means of STAT1 phosphorylation) or IL-4 (evaluated by STAT6 phosphorylation) were detected (data not shown). Finally, addition of healthy control monocytes or B cells completely or partially restored (respectively) the proliferation defect of T cells from PBMCs of 2 IKZF1
N159S patients when stimulated with soluble anti-CD3/CD28. This suggests that functionally defective monocytes and/or the absence of B cells in IKZF1 N159S patients contribute to the T cell proliferation defect ( Figure 4C) .
Collectively, these observations indicate that heterozygous mutations yielding IKZF1 N159S/T are associated not only with a CID affecting B and T cell function, but also with myeloid abnormalities suggestive of a multilineage hematopoietic defect. Myeloid defects could also directly contribute to the T cell defects in vivo in the patients, as addition of monocytes from healthy donors rescued T cell proliferative response from PBMCs of patients in vitro. This defective T cell proliferative response might be the result of impaired cytokine production by monocytes and/or antigen presentation, both involved in T cell activation, in addition to the already-established intrinsic T cell defects demonstrated in these patients.
Importantly, the clinical and biological picture associated with IKZF1 N159S and IKZF1 N159T mutations, including the susceptibility to T-ALL development, strongly contrasts with the B cell-centric deficiency caused by previously reported haploinsufficient IKZF1 mutations (2, 18, 19, 22) . Therefore, we hypothesized that mutations IKZF1 N159S and IKZF1 N159T may act through a different mechanism than haploinsufficiency.
Dominant-negative behavior of IKZF1 N159S and IKZF1
N159T mutations. Expression levels and functional effects of mutant proteins IKZF1 N159S and IKZF1 N159T were assessed in patients' cells as well as in vitro expression experiments. IKZF1 expression was evaluated by means of flow cytometry (PBMCs from patients C1 and D1) and Western blot analysis using T cell blasts from patient G1 ( Figure  5A ). No protein expression differences were noticed between cells from patients and healthy controls. Mutant proteins IKZF1 N159S and IKZF1 N159T were expressed in transiently transfected HEK293T cells and compared with WT IKZF1 or with the previously described haploinsufficient IKZF1 R162Q mutant protein. All proteins were found to be expressed at similar levels, indicating that N159S and N159T mutants are expressed and stable (Figure 5B) . Binding of WT and mutant IKZF1 proteins (alone or in combination) to the PC-HC sequences of the γ satellite region of chromosome 8 (γ-Sat8) or IKAROS consensus-binding sequence 4 (IK-bs4) was evaluated by electrophoretic mobility shift assay (EMSA) using protein extracts from HEK293T transfected cells. None of the 3 mutant proteins were able to bind to γ-Sat8 or IK-bs4, and 40%-50% reduction in binding was evidenced in the 50:50 mutant/WT protein combination tested ( Figure 5, C and D) .
The function of IKZF1 N159S and IKZF1 N159T proteins was assessed by their ability to dimerize, migrate to the nucleus, and form foci by binding to PC-HC, as previously reported (14, 21) . Mutant proteins IKZF1 N159S and IKZF1 N159T were able to dimerize with WT IKZF1 ( Figure 5E ) and migrate to the nucleus ( Figure 6A and Supplemental Figure 6 ). IKZF1 observed after addition of either healthy control monocytes or B cells, respectively. This finding could have relevant clinical implications in patients undergoing HSCT, as lymphoid engraftment alone or mixed chimerism may not suffice to rescue the phenotype. The T cell proliferation defect was also associated with an impaired CD25 upregulation after TCR engagement, which could explain why IL-2 did not rescue the defective T cell proliferation. However, all these features may also be in part secondary to a T cell developmental defect resulting in hyporeactive T cells with low-density CD45RA expression (27) . Importantly, 1 patient (G1) had preserved memory T cells but still exhibited the same T cell proliferation and Th polarization defect, which suggests that the absence of memory T cells in the other patients was not solely responsible for this functional defect. Third, as opposed to most forms of CID, which are characterized by a depletion in naive and accumulation of memory T cells (28) , there was a profound defect in memory T cell acquisition and maintenance both in vivo and in vitro, which points toward a specific role for IKZF1 in the development of memory T cells. Interestingly, this particular feature was almost exclusively described to be associated with genetic defects leading to loss of function of NF-κB activation, such as IKBA, IKBKB, CARMIL2, or BCM (BCL10, CARMA1, and MALT1) deficiencies (29-31). We therefore evaluated the NF-κB canonical pathway (by means of IκBα degradation and p65 phosphorylation in 2 patients, C1 and G1) and did not find any evidence for abnormal NF-κB signaling (not shown). These findings do not exclude a more downstream signaling defect at the DNA-binding level or other NF-κB regulatory defects. Indeed, Trung et al. (32) have recently shown that lymphoid hyperconserved core promoter-associated M4 motifs could constitute a binding platform for IKZF1 and NFκB1, with optimal signaling when both proteins are present.
The spectrum of manifestations associated with IKZF1 N159S/T also include various myeloid defects. While eosinopenia was present in all patients tested, neutropenia was detected in most but not all affected individuals, imposing an increased risk factor for infections. Even if monocyte counts remained normal, in vitro functional evaluation demonstrated a severe impairment in the production of cytokines in response to TLR1, TLR2, TLR4, TLR5, and TLR6 stimulation, and transcriptome analysis revealed an abnormal phenotype. In addition, myeloid DCs were severely diminished in the patients tested. This latter finding could be involved in Cryptosporidium susceptibility, as was diagnosed in 1 patient (A1). Cryptosporidiosis is associated with a restricted number of primary immune deficiencies, including CD40 ligand (33), MHC class II (34), and IL-21 receptor deficiencies (35) , all defects characterized by impaired crosstalk between T cells and antigen-presenting cells. MHC class II expression was normal in all patients tested. CD40L upregulation and CD40 binding were normal in 3 patients (C1, D1, and G1) but reduced in 1 (A1) (data not shown) who presented with cryptosporidiosis. As CD40L expression was evaluated after standard PMA/ionomycin stimulation, we cannot exclude that under physiologic T cell activation conditions a more consistent CD40L upregulation defect could be unveiled (as shown with CD25) and therefore contribute to increased Pneumocystis and Cryptosporidium susceptibility. The same rationale applies to the role of IL-21 signaling (not tested).
mycobacterial infections (respectively) (23) (24) (25) . All together, these preserved mechanisms might help to reduce the spectrum and clinical severity of certain infectious diseases in these individuals. Of note, autoimmunity and/or atopy were not detected in these patients despite low regulatory T cell numbers or/and increased DNT cell values. The drastic decrease in B cell and plasma cell numbers, as well as memory T cell numbers, together with defective Th2 polarization, eosinopenia, and low-to-undetectable levels of IgE, might prevent the expression of such symptoms. This novel CID displayed a complex T cell deficiency. First, most of the T cells were of a naive Th0-like phenotype but uniformly showed a decreased level of CD45RA expression associated with a recent thymic emigrant (RTE) phenotype (CD31 + ). These features may be useful for screening patients with CID in settings where a dominant-negative IKZF1 defect is suspected. T cell receptor excision circles (TRECs) were evaluated in 3 patients to further confirm the RTE status of these cells (26) . TRECs were in normal range in 2 patients and elevated in 1 patient (Supplemental Figure 2C ), which suggests that CD31 expression on naive T cells did not completely correlate with an RTE phenotype in our patients. Thus, CD31 dysregulation might be part of the defects associated with IKZF1 N159N/T mutations. Furthermore, transcriptome analysis of CD4 + naive T cells (CD3
) from patients with IKZF1 N159S/T mutations showed striking differences in terms of up-and downregulated genes when compared with CD4 + naive T cells from healthy controls and a patient carrying haploinsufficient mutation IKZF1 H167R (Supplemental Figure 2A) . These data confirmed that circulating naive T cells in IKZF1 N159S/T patients are abnormal and are also different from those in patients carrying haploinsufficiency mutations. These results could be indicative of abnormal lymphopoiesis, which may contribute to the risk for T-ALL in patients carrying dominant-negative IKZF1 N159N/T mutations, as they are reminiscent of the early T cell development abnormalities increasing the risk for T cell leukemia/lymphoma as seen in the Plastic/+ mice also carrying a dominant-negative heterozygous missense mutation (14, 15) . Interestingly, TCR-Vβ flow cytometric repertoire and TCR-Vα spectratyping showed a normal T cell distribution, which suggests that T cell thymic education was not obviously impacted in IKZF1 N159S/T patients (data not shown). Further studies are warranted in order to better characterize these T cells. As with CD4 + naive T cells, transcriptome analysis of monocytes from IKZF1 N159S/T patients also revealed marked differences when compared with healthy controls or the haploinsufficient IKZF1 H167R mutated patients (Supplemental Figure 2B ). Altogether these data correlate with the lack of abnormal T cell or monocyte phenotype in the IKZF1-haploinsufficient patients.
Second, peripheral blood T cells exhibited variably impaired proliferation defects depending on the stimulus and decreased IFN-γ, TNF-α, IL-4, IL-6, and IL-17A production indicative of a global defective Th polarization, in which cells seem arrested in a Th0-like phenotype. The observation that T cell proliferation was abnormal in response to recall antigens or to low concentrations of anti-CD3 suggests the possibility of an additional defect affecting accessory cells. Consistent with this hypothesis were the findings of low numbers of myeloid DCs and impaired cytokine production by monocytes in response to several TLR agonists. Furthermore, total or partial correction of T cell proliferation was the somatic mutation IKZF1 N159S has been found in patients with B-ALL (37). Our study suggests that carriers of germline IKZF1 N159S mutation likely have an increased risk of developing T-ALL. Thus, we searched for IKZF1 N159S or IKZF1 N159T mutations in a cohort of patients with T-ALL, for which tumor material had been analyzed by next-generation sequencing. One tumor sample was found to contain a somatic heterozygous mutation, IKZF1
N159S
, and was not detected in the PBMCs of the patient after induction of remission, which ruled out that the mutation was germinal, and 100% of leukemic cells were found to carry the IKZF1 N159S mutation (D. Boutboul, S. Latour, L. Lhermitte and V. Asnafi, unpublished observations). Altogether, these observations indicate that mutation IKZF1 N159S can be a leading genetic event associated with leukemogenesis, suggesting that there may be a phenotypic continuum between somatic and germline IKZF1 N159S mutations.
Interestingly, patient E1 was first suspected to have GATA2 deficiency based on bone marrow hypocellularity, monocytopenia, and the complete absence of B cells. Haploinsufficiency of GATA2, another transcription factor expressed in hematopoietic cell progenitors, is a monogenic dominant immune deficiency leading to myeloid and lymphoid defects and increased susceptibility to hematologic malignancies (36) , characteristics akin to those of the CID caused by IKZF1 N159S/T mutations described herein. Interestingly, a crosstalk between Ikaros and Gata2 transcription factors was clearly established in mouse models, as Ikaros expression is differentially regulated by Gata2 and Gata1 during megakaryocytic development (7) .
Patients with somatic and germline IKZF1 mutations are associated with increased susceptibility to and poor outcome from selected lymphoid malignancies including ALL. In particular, IKZF1 foci were counted in 100 transfected NIH 3T3 cells (n = 100) for each condition. Observer bias was eliminated by coding the slides prior to inspection. Statistical analysis was performed between the different groups with a 1-way ANOVA test. Horizontal lines represent the median ± 95% confidence interval (CI). ****P < 0.0001. (C) The experiment in A was repeated twice adding 3:1 and 1:3 WT/Mut ratio, and foci were enumerated as described in B. For each condition, 90-121 transfected cells were counted, and statistical analysis was performed between the different groups with a 1-way ANOVA test. Horizontal lines represent the median ± 95% CI. ****P < 0.0001.
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sequence with the PRMD9 ZNF8-11 (see Figure 1C) , whose 3D structure has been solved in complex with a hot-spot oligonucleotide (20) . Template selection was based on the results from Phyre2 (Structural Bioinformatics Group; fourth hit, confidence 99.7) and I-TASSER (Zhang Lab, https://zhanglab.ccmb.med.umich.edu/I-TASSER/; first hit, normalized Z score 6.59), selecting for modeling arrays of fourth consecutive ZF, in complex with DNA. Molecular graphics and analyses were performed with the UCSF Chimera package (39) . Sequence alignments were rendered using ENDscript (40) . Sanger sequencing. Selected NGS results were confirmed by Sanger sequencing. Specifically, IKZF1 coding exon 5 was amplified by PCR with exon-specific oligonucleotide primers and GoTaq Hot Start Polymerase (Promega) (forward primer sequence: CCCCCGTGGGAAA-CAACTTT; reverse primer sequence: GAGGGATCAGGGTTAGC-CA). Purified PCR products were directly sequenced with BigDye Terminators (version 1.1, Thermo Fisher Scientific) and were analyzed on a 3130xL Genetic Analyzer (Applied Biosystems).
Plasmid constructs, cell transfections, and infections. Human IKAROS family zinc finger 1 (IKAROS) (IKZF1; NM_006060) cDNA was synthesized (GeneScript) and subcloned into the mammalian expression vector pcDNA3-HA or pCMV6-AC-DDK (Origene), pcDNA3.1D/V5-His-TOPO (Invitrogen). Indicated mutants for IKZF1 were generated based on the site-directed mutagenesis protocol with AccuPrime Pfx DNA Polymerase (Thermo Fisher Scientific) followed by DpnI treatment (Life Technologies) or Q5 Hot Start High Fidelity polymerase (Thermo Fisher Scientific), followed by KLD treatment (NEB). Human IKAROS family zinc finger 3 (IKZF3/AIOLOS) ORF clone (pcDNA3.1-AIOLOS, NM_012481) was purchased from GenScript.
Cell culture. PBMCs were isolated by the use of Ficoll separation (Lonza). PBMCs were cultured in RPMI 1640 with 10% fetal bovine serum, 2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Thermo Fisher Scientific) at 37°C in a humidified 5% CO 2 incubator. NIH 3T3 and HEK293T (ATCC CRL-1658 and CRL-11268) cells were cultured in DMEM with 10% fetal bovine serum, l-glutamine, and penicillin/streptomycin. Expansion of T cell blasts was obtained by incubating PBMCs for 72 hours with PHA (2.5 μg/ml, Sigma-Aldrich) in Panserin 401 (PAN Biotech) supplemented with 5% human male Ab serum (BioWest), penicillin (100 U/ml), and streptomycin (100 μg/ml). After 3 days, dead cells were removed by Ficoll-Paque density gradient, and blasts were maintained in culture with IL-2 (100 UI/ml).
Fluorescence microscopy. NIH 3T3 cells (0.8 × 10 5 to 1 × 10 5 ) were seeded onto coverslips in 6-well plates. The next day, cells were transfected with indicated plasmid by Effectene (QIAGEN) or Lipofectamine 2000 (Thermo Fischer Scientific) according to the manufacturer's instructions. The cells were washed twice in PBS, fixed for 10 minutes in 4% paraformaldehyde, and permeabilized for 15 minutes in 0.1% Triton X-100 in PBS at room temperature. The cells were then incubated for 30 minutes in blocking buffer (PBS with 10% FBS and 0.1% Triton X-100) and then incubated for 2 hours with rabbit anti-IKZF1 monoclonal antibody (ab191394, Abcam, Figure 6A and Supplemental Figure 7A ), anti-HA mouse monoclonal antibody (MMS-101P, Covance, Supplemental Figure 6 and Supplemental Figure 7C ), anti-FLAG rabbit polyclonal affinity antibody (F7425, Sigma-Aldrich, Supplemental Figure 6 ), or anti-IKZF3 rabbit mAb (D1C1E, Cell Signaling Technology, Supplemental Figure 7) . The cells were washed with PBS and incubated in blocking We show that germline IKZF1 N159S/T mutations behave in a dominant-negative fashion, contrasting with the germline and not-fully-penetrant haploinsufficient mutations previously described (18) . A previous work by Hoshino et al. (19) did not show dominant-negative behavior of the IKZF1 N159S mutation, but this issue was not specifically addressed, as no enumeration of foci using different WT/mutant protein ratios was performed in their study. Moreover, the immunological and clinical phenotypes associated with IKZF1 N159S/T mutations are broader, more severe, and consistently characterized by an early-onset CID in all patients studied. In addition, the fact that germline IKZF1 N159S/T mutations were apparently de novo in all patients tested and no asymptomatic relatives or healthy individuals were detected suggests -although it cannot be formally assessed -a highly or even fully penetrant dominant disease (in contrast to that associated with haploinsufficient mutations). However, while T and B lymphoid defects were always present in IKZF1 N159S/T patients, myeloid defects were variable, which suggests additional genetic and/or environmental factors. Interestingly, haploinsufficient mutations preserving one functionally active allele do not seem to impact T cell and myeloid biology in a clinically relevant manner (15, 18, 22) , which demonstrates that one fully functional IKZF1 copy is sufficient to retain normal T cell and myeloid functions.
Like haploinsufficient IKZF1 mutants, IKZF1 N159S/T proteins failed to form foci with PC-HC localization and to bind γ-Sat8 and IK-bs4 DNA sequences, known targets for IKZF1. However, in contrast to their haploinsufficient counterparts, dominantnegative mutations inhibit formation of foci by WT IKZF1. Selected in silico modeling of IKZF1 3D structure predicted that serine and threonine substitutions of asparagine 159 may retain the ability to bind DNA but with altered specificity (Supplemental Figure 8 and data not shown). Therefore, some weak non-PC-HC DNA fixation of IKZF1 N159S/T could help explain its dominant effect. Moreover, this potentially preserved DNA-binding ability could also modify the binding of WT IKZF1 and other partners, when heterodimerized with mutant IKZF1 N159S/T , as suggested by the absence of AIOLOS focus formation when coexpressed with IKZF1 N159S/T (Supplemental Figure 7) . More studies are needed to address the putative target sequences of IKZF1 N159S/T dominant-negative mutants, ideally by use of a lymphoid system that expresses individual IKZF1 partners.
Taken together, these findings expand the clinical and biological spectrum associated with germline IKZF1 loss-of-function mutations in humans. These observations also provide insights into nonredundant functions of hematopoietic transcription factors, highlighting the key role of IKZF1 in hematopoiesis and T cell memory acquisition in humans.
Methods
Whole-exome sequencing and bioinformatics. See Supplemental Methods for whole-exome sequencing (WES) details for patients A1, C1, D1, E1, and G1. For patients B1 and F1, WES details have been previously provided elsewhere (2, 19) . DNA sequencing exome data have been deposited into the NCBI's Sequence Read Archive (SRA SRP136278).
Sequence analysis and molecular modeling. The model of the 3D structure of the IKZF1 ZF1-4 DNA-binding domains was built with Modeller version 9.15 (38) , on the basis of the alignment of its Cytokine measurement. For intracellular staining of cytokines, day-7 T cell blasts were stimulated overnight with anti-CD3/CD28-coated beads (Invitrogen) or PMA (20 ng/ml) plus ionomycin (1 μg/ml) in the presence of brefeldin A (GolgiPlug, BD). Cells were fixed and permeabilized with the BD Cytofix/Cytoperm Plus kit (BD Pharmingen) according to manufacturer's instructions. Cells were then labeled with APC-anti-IFN-γ (mouse IgG1, 4S.B3) or PE-anti-IL2 (rat IgG2a, MQ1-17H12) and isotype-matched monoclonal antibodies purchased from BioLegend. Cells were finally collected, washed, and stained with BV785-anti-CD3, BV510-anti-CD4, and/or BV650-PE-anti-CD8 mAbs and analyzed by flow cytometry.
For further identification of CD4 + Th1, Th2, and Th17 populations, total PBMCs were stimulated with PMA (100 ng/ml, Sigma-Aldrich) and ionomycin (1 μM, Sigma-Aldrich) for 6 hours in the presence of brefeldin A (10 μg/ml, Invitrogen). The stimulated cells were stained with PerCP-Cy5. buffer for 1 hour with secondary antibodies conjugated with Alexa Fluor 546 (red color, Thermo Fisher Scientific) to reveal anti-IKZF1 staining, Alexa Fluor 488 (green color) to reveal anti-HA staining, or Alexa Fluor 568 (red color) to reveal anti-FLAG or anti-IKZF3 staining. Cells were washed and mounted on slides with VECTASHIELD Mounting Medium (Vector Laboratories). Images were collected by a ZOE fluorescent cell imager (Bio-Rad) or Leica SP8 STED confocal microscope (Leica Microsystems). For quantification of foci, foci per cell were manually counted under a confocal microscope on slides that were anonymized to the observer. About 100 cells were analyzed for each condition (see legend of Figure 6) .
Lightshift chemiluminescent EMSA. HEK293T cells were transfected with pCMV-AC-DDK, WT or mutant, and nuclear extracts were prepared with NE-PER nuclear extract kit according to the manufacturer's instructions (Thermo Fisher Scientific). Gel mobility shift assays were performed with LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientific) according to the manufacturer's instructions. DNAprotein complexes were separated on 6% Novex TBE gels with 0.5× TBE. Sequences for human probes were as follows: γ satellite from human chromosome 8 (γ-Sat8) (forward: 5′-BIOTIN-GCGAGACCGCAGG-GAATGCTGGGAGCCTCCC; reverse: 5′-BIOTIN-GGGAGGCTC-CCAGCATTCCCTGCGGTCTCGC) (41); IKAROS consensus-binding sequence 4 (IK-bs4) (forward: 5′-BIOTIN-TGACAGGGAATACACAT-TCCCAAAAGC; reverse: 5′-BIOTIN-GCTTTTGGGAATGTGTATTC-CCTGTCA). EMSA bands were quantified by the Bio-Rad Image Lab program. Data were normalized with the binding of the extracts from cells transfected, with WT IKZF1 as 100%.
Bone marrow staining. Bone marrow flow cytometric analysis was performed on a FACSCanto II flow cytometer (BD Biosciences), and immunohistochemistry was performed on bone marrow core biopsy sections by the Ventana automated staining system (Roche), as previously described (42) . For the flow cytometric analysis, 500,000 total events were captured per bone marrow sample. Cells depicted are gated on all CD34 + cells and all CD19 + cells in bone marrow aspirate from a healthy control marrow (37,000 gated events) and patient B2 (14,000 gated events). The following antibodies (clone) were used: CD34 (8G12), CD19 (SJ25C1), TdT (E17-1519, BD Biosciences). Cell proliferation. Human PBMCs were isolated by densitygradient centrifugation with Ficoll-Paque PLUS (GE Healthcare), washed twice in PBS, and cultured in complete RPMI-1640 medium containing 10% FBS and penicillin-streptomycin-glutamine (Life Technologies) at 37°C in a humidified 5% CO 2 incubator. PBMCs, either freshly isolated or thawed from liquid nitrogen−stored samples, were incubated with CellTrace violet Cell Proliferation Kit (1 μM; Invitrogen). After 20 minutes, 10 volumes of RPMI/10% FBS were added, and the cells were centrifuged and washed twice more with RPMI/10% FBS. A total of 1 × 10 5 cells were seeded into 96-well plates, stimulated with coated anti-CD3 (precoated overnight at 4°C, 1 or 10 μg/ml, eBioscience), soluble anti-CD3 antibody and anti-CD28 antibody (1 μg/ml each, clones 16-0037 and 16-0288, eBioscience), anti-CD3/CD28-coated beads (Invitrogen), or PHA (1 μg/ml, Sigma-Aldrich) as indicated in the figures. IL-2 was used at a final concentration of 100 UI/ml. Cells were stained with fluorochrome-conjugated CD4 and CD8 antibodies (BD Biosciences) for 30 minutes at 4°C (in the dark). Cells were washed with PBS twice, and cells were acquired and analyzed by flow cytometry (Becton Dickinson FACSCanto II) and FlowJo software (TreeStar). jci.org Volume 128 Number 7 July 2018
Statistics. Where indicated, data were by 1-way ANOVA test with GraphPad Prism software (GraphPad). The differences were considered significant when P was less than 0.05.
Study approval. All patients or their guardians provided written informed consent. The study and protocols conform to the 1975 Declaration of Helsinki under institutional review boards, as well as to local legislation and ethical guidelines from the Comité de Protection des Personnes de l'Ile de France II and the French advisory committee. Blood from healthy donors and patients was obtained under approved protocols (see above) at the NIH, internal, and institutional review boards, which also allow for the collection and use of patients' family history and pedigrees for publication. All procedures were based on standard of care, and established clinical guidelines were followed. EasySep human naive CD4 + T cell isolation kit from patients' and controls' PBMCs; CD14 + cells (monocytes) were enriched by the EasySep human monocyte enrichment kit (STEMCELL Technologies) from patients' and controls' PBMCs and stimulated with LPS (100 ng/ml) for 24 hours. Purity was greater than 90% for both populations studied. Targeted RNA sequencing library preparation was carried out with an Ion AmpliSeq Transcriptome Human Gene Expression Kit (Life Technologies), which is designed to profile more than 20,000 distinct human reference sequence genes with a highly multiplexed amplification method. Each amplicon represents a unique targeted gene (one transcript per gene). The average size of each amplicon is approximately 150 bp. For library preparation, each sample was run in duplicate, and a cDNA library was first generated from a minimum of 10 ng of total RNA. The cDNA was barcoded and amplified with Ion AmpliSeq technology, and the amplified cDNA Libraries were evaluated for quality and quantified with Agilent Bioanalyzer high-sensitivity chip. Libraries were then diluted to 100 pM and pooled equally, with 4 individual samples per pool. Pooled libraries were amplified and enriched with the Ion Chef System (Life Technologies). Templated libraries were then sequenced on an Ion Torrent Proton sequencing system (Life Technologies) with Ion PI HiQ kit and chip version 3. We performed gene-level differential expression analysis of targeted RNA sequencing data on naive CD4 + cells and monocytes with the Bioconductor DESeq2 package (43) . Briefly, for each cell type (naive CD4 + and monocytes), we merged raw count files, systematically filtered out transcripts with low expression, and defined groups (control, patient), genotypes (IKZF1 WT, IKZF1 mutant), and phenotypes (healthy, haploinsufficient, dominant negative). The genotype and phenotype factors were combined to assess the interaction of these 2 factors. We then constructed a DESeq2 object, estimated size factors, log 2 -normalized counts, collapsed the technical replicates, contrasted groups, annotated results, transformed the data (variance stabilization), and performed Pearson correlation. RNA sequencing data have been deposited into the NCBI's Gene Expression Omnibus databases (GEO GSE112706 and GSE112707) and Sequence Read Archive database (SRA SRP136927 and SRP136939).
